Significant EU funding for implementing value-based cancer care at European cancer hospitals
“To implement value-based cancer care, real-world data on the cost-effectiveness of treatments is needed in real-time”, states the project lead, senior medical director in oncology, Johanna Mattson.
ONCOVALUE project aims to increase the capabilities of European cancer hospitals to easily and timely collect real-world data (RWD). Systematic collection and analysis of clinical data is needed for the continuous development of treatment and improvement of outcomes. Real-time high-quality clinical data also supports the decision making of regulatory and HTA bodies on the value of novel cancer therapies. At its best ONCOVALUE project may also enhance the commissioning of effective novel therapies. Additionally, RWD also enables the identification of the patient groups that do not get any benefit of a specific therapy, thus helping to target the treatments to patients with favorable response.
The consortium partners aim to develop novel AI-based tools to automate the collection and analytics of clinical data. Additionally, an end-to-end infrastructure for RWD reporting in health regulatory and HTA decision-making will be built. Furthermore, ONCOVALUE will ensure the implementation of the developed guidelines and methodologies, by providing trainings 1) for the collection and management of high-quality RWD in European cancer centers and 2) for the analysis of this data by HTA and regulatory bodies.
By opening the door to widespread regulatory and HTA integration of RWD, ONCOVALUE will lead to safer, more efficient, and affordable therapies, technologies, and digital solutions for (personalized) cancer care. As such, ONCOVALUE is positioned to contribute to increased cost-effectiveness and sustainability of cancer care. Systematic collection and evaluation of the patient reported outcomes will also lead to improved well-being of the patients. Subsequently, on the long-term implementation of value-based cancer care at European cancer hospitals will aid in reducing the growing burden of cancer treatment in the EU and worldwide.
The Consortium consists of several leading European cancer hospitals and industry partners specialized in artificial intelligence, machine learning, and communications. The proposal preparation was supported by Ttopstart, a consultancy company specialized in EU-funding.
The ONCOVALUE Consortium: HUS Helsinki University Hospital (FI), Stichting Het Nederlands Kanker Instituut-Anton (NL), Elevate BV (NL), IQVIA Solutions BV (NL), Rigshospitalet Copenhagen University Hospital (DK), BC Platforms LTD OY (FI), Siemens Healthcare GMBH (GER), Instituto Portugues de Oncologia do Porto (PT), Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IT), CIAOTech Srl (IT), TTOPSTART BV (NL).
For more information:
Johanna Mattson, Senior Medical Director in Oncology, HUS Helsinki University Hospital
firstname.surname@hus.fi, +358 50 427 9165
Keywords
Images
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
En ny upptäckt av en genetisk defekt löste gåtan om allvarlig mononukleos28.3.2024 09:35:39 EET | Tiedote
En ny ärftlig sjukdom som tar sig uttryck i kraftig mononukleos hittades hos finländare. Den genetiska defekten kan leda till behandling av många olika sjukdomar.
Uusi geenivirhelöytö ratkaisi vakavan mononukleoosin arvoitusta28.3.2024 09:35:39 EET | Tiedote
Suomalaisilta löydettiin uusi perinnöllinen sairaus, joka ilmenee rajuna mononukleoosina. Geenivirhe voi johdattaa monien eri sairauksien hoitoihin.
New gene defect discovery helps to unlock the mystery of severe infectious mononucleosis28.3.2024 09:35:39 EET | Press release
A new hereditary disease was found in Finns, which manifests as severe infectious mononucleosis. The genetic defect can lead to the treatment of many different diseases.
Syöpään sairastuneille apua sairastumiskriisin27.3.2024 13:53:19 EET | Tiedote
HUSin Psykiatriassa on kehitetty syöpään sairastuneille sairastumiskriisiin liittyvä terapeutin tukema digitaalinen hoito-ohjelma.
Artificiell intelligens hjälper oss identifiera frakturer, bentumörer och nekroser från röntgenbilder27.3.2024 09:11:25 EET | Tiedote
Algoritmerna för djupinlärning är snabbt på väg att inta en central roll i klassificering som rör medicinsk bildkategorisering och diagnostik. Tre artiklar från HUS handkirurgi som publicerats i internationellt referentgranskade tidningar lyfter fram möjligheterna med artificiell intelligens då det gäller att förbättra patientvården.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom